History Article
Close
This entry was posted on May 28, 2014 at 19:18.
The last change is the May 28, 2014 at 22:02.
The Ministry of Health has requested damages in the amount of EUR 1,200 million for three years to companies Novartis, Roche and Hoffmann for the story of the marketing of the drugs Lucentis and Avastin. The ministry has instead requested a compensation of 14 million company Pfizer.
It is a maxirisarcimento one billion and 200 million euro for the costs incurred by the NHS due to the cartel offense between Roche and Novartis which has led to the marketing of a drug against macular much more expensive than another. It is the demand shock that the Ministry of Health is to Roche and Novartis after the case Lucentis-Avastin, already cost the two giants farmacuetici a fine Authority. The ministry said in a statement, “following the resolution AGCM 24823 of February, 2014, described the behavior of company F. Hoffmann-La Roche Ltd., Roche Spa, Novartis AG and Novartis Pharmaceuticals S.pA. as “a horizontal agreement restricting competition aimed at the commercialization of the drug Lucentis much more expensive drug Avastin, equivalent to it”, has required pharmaceutical companies to the aforementioned compensation for all damage to property (approximately 45 million in 2012, 540 million in 2013, and 615 million in 2014) and non-property wrongfully caused to the NHS. ”“The President of the Italian Ophthalmological Society once again confounds and mystifies. Roche has confidence in the Tar today that the decision was also requested from us. ” The exact pharmaceutical group Roche on the case of maxi-arranged by the Antitrust Authority fined the company and Novartis, for an agreement deemed anti-competitive marketing of drugs Avastin (bevacizumab) and Lucentis (ranibizumab), on the decision of Roche do not ask for the suspension of the penalty today before the TAR of Lazio.
A choice “dictated solely by the desire to accelerate the discussion on the merits of the measure, in order to reach such a judgment without any further delay,” the company said. “It is not surprising that the president of the Soi has once again confused and misrepresented what happened, extending its self from the scientific to the legal system,” says Roche. “The decision to accelerate as much as possible the decision at first instance by the Tar is dictated by the determination of Roche as soon as possible to clarify the correctness of their actions, hoping thus to curb the uncontrollable proliferation of inaccuracies that the president of Soi not miss to dispense with almost daily. Roche is confident that it can be the Tar Lazio the forum in which to discuss in depth the issues under appeal, including whether – as competence – the scientific profiles that the President of the SOI is determined to trivialize. ” It is not long in coming also statement of Novartis. According to the company headquartered in Basel, the demand for maxirisarcimento from the Ministry of Health for the case Avastin-Lucentis is “unfounded.” The company also stated that it did not “received any notification at the time.” Novartis’ firmly rejects accusations of anti-competitive practices and this has challenged the decision of the Competition Authority before the TAR of Lazio: the process is still ongoing and the ruling is expected later this year. ” Therefore, the pharmaceutical company writes, “any claim is groundless as well as the figures indicated in the notice of the Ministry that find no correspondence with the facts: the expenditure generated by Lucentis borne by the NHS in January-September 2013 amounted to 38.6 million euro, in line with the data recorded in 2012. ” Novartis’ reaffirms the correctness of its actions and has always acted in full compliance with Italian and European legislation, which is now being challenged by a “controlled liberalization” off-label use of Avastin, in contravention of rules and established processes and shared at Community level, which were designed to protect the health of the patient and ensure the sustainability of the system. Novartis will make use of their rights of defense in all relevant fora. “© ALL RIGHTS RESERVED
Permalink
No comments:
Post a Comment